NASDAQ:CVKD Cadrenal Therapeutics Q1 2025 Earnings Report $1.33 +0.01 (+0.76%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cadrenal Therapeutics EPS ResultsActual EPS-$2.09Consensus EPS -$1.64Beat/MissMissed by -$0.45One Year Ago EPSN/ACadrenal Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACadrenal Therapeutics Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time4:00PM ETUpcoming EarningsCadrenal Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cadrenal Therapeutics Earnings HeadlinesCadrenal Therapeutics CEO to Present at Lytham Partners Fall 2026 Investor Conference September 21 at 4:51 PM | quiverquant.comQCadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor ConferenceSeptember 21 at 4:30 PM | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Cadrenal Therapeutics Inc.September 4, 2026 | barrons.comCadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment ConferenceSeptember 3, 2026 | globenewswire.comCVKD: Advancing Partnering Process for Cardiac Acute Critical Care FranchiseAugust 31, 2026 | finance.yahoo.comSee More Cadrenal Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cadrenal Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cadrenal Therapeutics and other key companies, straight to your email. Email Address About Cadrenal TherapeuticsCadrenal Therapeutics (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company focused on developing therapies for patients who require long-term anticoagulation. The company’s lead product candidate is tecarfarin, an oral vitamin K antagonist designed for chronic anticoagulation in patients with implanted cardiac devices, including mechanical heart valves and left ventricular assist devices (LVADs). Tecarfarin is intended to provide anticoagulant activity through a metabolic pathway that differs from warfarin, with the goal of reducing certain drug-drug interactions and offering a potential treatment option for patients who are difficult to manage with existing anticoagulants. Cadrenal has studied tecarfarin in patients with mechanical circulatory support devices and is advancing development for additional high-risk cardiovascular indications. Cadrenal Therapeutics is based in the United States and was established to develop tecarfarin and related cardiovascular therapies. The company is led by Quang X. Pham, who serves as chief executive officer and chairman. Its development efforts are primarily directed toward the U.S. market and regulatory pathway, with a focus on addressing unmet needs in patients requiring durable anticoagulation.View Cadrenal Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
